MP66-12 A NOVEL CELL BASED MULTIPLEX BIOMARKER ASSAY FOR PROSTATE CANCER DETECTION IN URINE

Abstract

You have accessJournal of UrologyProstate Cancer: Basic Research V1 Apr 2015MP66-12 A NOVEL CELL BASED MULTIPLEX BIOMARKER ASSAY FOR PROSTATE CANCER DETECTION IN URINE Shyh-Han Tan, Kristen P. Nickens, Amina Ali, Tatiana Scoggin, Lakshmi Ravindranath, David G. McLeod, David Tacha, Shiv Srivastava, Isabell Sesterhenn, and Gyorgy Petrovics Shyh-Han TanShyh-Han Tan More articles by this author , Kristen P. NickensKristen P. Nickens More articles by this author , Amina AliAmina Ali More articles by this author , Tatiana ScogginTatiana Scoggin More articles by this author , Lakshmi RavindranathLakshmi Ravindranath More articles by this author , David G. McLeodDavid G. McLeod More articles by this author , David TachaDavid Tacha More articles by this author , Shiv SrivastavaShiv Srivastava More articles by this author , Isabell SesterhennIsabell Sesterhenn More articles by this author , and Gyorgy PetrovicsGyorgy Petrovics More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2365AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Over one million men undergo prostate biopsies annually in the US, a majority of them due to elevated serum PSA. More than half of the biopsies turn out to be negative for prostate cancer (CaP). The limitations of PSA test as well as the biopsy procedure have prompted to develop more precise CaP detection assays in urine- (e.g. PCA3, TMPRSS2-ERG) or blood (e.g. PHI, 4K). Here we describe the development and evaluation of a Urine CaP Marker Panel (UCMP) assay for sensitive and reproducible detection of CaP cells in post-digital rectal examination (post-DRE) urine. METHODS The cellular content of the post-DRE urine, was captured on translucent membrane for direct evaluation by microscopy and immunocytochemistry. The membranes placed on Cytoclear microscope slides were used for characterization of prostate epithelial cell by PSA and Prostein or tumor cells by ERG and AMACR protein markers. Immunostained cells were analyzed for quantitative and qualitative features and correlated with biopsy positive and negative status for malignancy. RESULTS Assay was optimized for single cell capture sensitivity and downstream evaluations by spiking known number of cells from established prostate cancer cell lines, LNCaP and VCaP, into cleared control urine. The cells captured from the post-DRE urine of subjects, obtained prior to biopsy procedure, were co-stained for ERG, AMACR, Prostein and PSA, rendering a whole cell based analysis and characterization. A feasibility cohort of 63 post-DRE urine specimens was assessed. Comparison of the UCMP results with the blinded biopsy results showed an assay sensitivity of 64% (16 of 25) and a specificity of 68.8% (22 of 32) for CaP detection by biopsy. CONCLUSIONS This pilot study assessing a minimally invasive prostate cancer detection assay with single cell sensitivity cell-capture and characterization from the post-DRE urine holds promise for further development of this novel assay platform. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e820 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Shyh-Han Tan More articles by this author Kristen P. Nickens More articles by this author Amina Ali More articles by this author Tatiana Scoggin More articles by this author Lakshmi Ravindranath More articles by this author David G. McLeod More articles by this author David Tacha More articles by this author Shiv Srivastava More articles by this author Isabell Sesterhenn More articles by this author Gyorgy Petrovics More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...